Drug Profile


Alternative Names: ACC 9653; ACC 9653-010; Cerebyx; Cereneu; Fosphenytoin sodium hydrate; Fostoin; NPC-06; PD 135711-15B; Pro-Epanutin; Prodilantin; Prophenytoin

Latest Information Update: 17 Jan 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Nobelpharma; Pfizer
  • Class Antiepileptic drugs; Hydantoins; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy
  • Discontinued Stroke

Most Recent Events

  • 17 Jan 2012 Launched for Epilepsy in Japan (IV)
  • 01 Jul 2011 Registered for Epilepsy in Japan (IV)
  • 30 Jun 2010 Preregistration for Epilepsy in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top